Blood pressure in early autosomal dominant polycystic kidney disease.

Polycystic kidney disease. HALTing PKD progression--revival of blood pressure control. Nat Rev Nephrol (2014) 0.75

Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2014) 5.01

Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.05

Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.05

Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med (2015) 1.04

Renal failure in cirrhosis. N Engl J Med (2009) 4.46

Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med (2013) 4.34

Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol (2010) 3.64

Diagnosis and treatment of acute tubular necrosis. Ann Intern Med (2002) 3.33

Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med (2007) 3.22

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol (2004) 2.69

Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol (2007) 2.20

Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease. Kidney Int (2010) 2.12

Modifier genes play a significant role in the phenotypic expression of PKD1. Kidney Int (2005) 2.03

Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol (2009) 2.02

Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis (2002) 1.92

Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur Heart J (2011) 1.88

Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol (2012) 1.80

Autosomal-dominant polycystic kidney disease in infancy and childhood: progression and outcome. Kidney Int (2005) 1.72

Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis (2008) 1.71

Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med (2014) 1.64

Best paper of the 1980s: National Institutes of Health Consensus Development Conference Statement: geriatric assessment methods for clinical decision-making. 1988. J Am Geriatr Soc (2003) 1.64

Glomerular hyperfiltration and renal progression in children with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2011) 1.62

The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol (2010) 1.59

Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol (2007) 1.55

Earlier diagnosis of autosomal dominant polycystic kidney disease: importance of family history and implications for cardiovascular and renal complications. Am J Kidney Dis (2005) 1.55

Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. Eur J Endocrinol (2011) 1.54

Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol (2009) 1.50

Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes. Am J Hypertens (2006) 1.47

Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail (2008) 1.45

Pathophysiological roles of arginine vasopressin and aquaporin-2 in impaired water excretion. Clin Endocrinol (Oxf) (2003) 1.39

Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol (2009) 1.36

Changing referral characteristics of patients with autosomal dominant polycystic kidney disease. Am J Med (2013) 1.34

Does 'asymptomatic hyponatremia' exist? Nat Rev Nephrol (2010) 1.30

Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation (2003) 1.28

Interaction among nitric oxide, reactive oxygen species, and antioxidants during endotoxemia-related acute renal failure. Am J Physiol Renal Physiol (2003) 1.28

Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. J Am Soc Nephrol (2005) 1.27

Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. Am J Physiol Renal Physiol (2005) 1.26

Increased left ventricular mass in children with autosomal dominant polycystic kidney disease and borderline hypertension. Kidney Int (2008) 1.21

Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc Natl Acad Sci U S A (2005) 1.20

Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol (2010) 1.20

Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med (2009) 1.19

Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol (2010) 1.19

Hypertonicity-induced aquaporin-1 (AQP1) expression is mediated by the activation of MAPK pathways and hypertonicity-responsive element in the AQP1 gene. J Biol Chem (2003) 1.14

Analysis of baseline parameters in the HALT polycystic kidney disease trials. Kidney Int (2011) 1.13

Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease. Liver Int (2007) 1.11

Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int (2002) 1.11

cAMP regulates vasopressin-induced AQP2 expression via protein kinase A-independent pathway. Biochim Biophys Acta (2006) 1.10

Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol (2007) 1.09

Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am J Hypertens (2004) 1.07

Developments in the management of autosomal dominant polycystic kidney disease. Ther Clin Risk Manag (2008) 1.06

Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol (2012) 1.06

Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 1.05

Aldosterone 'escape' vs 'breakthrough'. Nat Rev Nephrol (2010) 1.04

Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J Am Soc Nephrol (2008) 1.04

Congenital renal agenesis: case-control analysis of birth characteristics. Am J Kidney Dis (2002) 1.03

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol (2006) 1.02

Hyperosmolality in vivo upregulates aquaporin 2 water channel and Na-K-2Cl co-transporter in Brattleboro rats. J Am Soc Nephrol (2006) 1.02

Variation in age at ESRD in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2008) 1.02

Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens (2011) 1.02

Acute renal failure independently predicts mortality after myeloablative allogeneic hematopoietic cell transplant. Kidney Int (2005) 1.01

Cardiorenal versus renocardiac syndrome: is there a difference? Nat Clin Pract Nephrol (2007) 1.00

Molecular mechanisms of angiotensin II stimulation on aquaporin-2 expression and trafficking. Am J Physiol Renal Physiol (2011) 1.00

Role of AQP1 in endotoxemia-induced acute kidney injury. Am J Physiol Renal Physiol (2008) 1.00

Blood urea nitrogen a marker for adverse effects of loop diuretics? J Am Coll Cardiol (2011) 0.99

Protective effect of renal denervation on normotensive endotoxemia-induced acute renal failure in mice. Am J Physiol Renal Physiol (2002) 0.98

Comparison of three methods to quantify urinary aquaporin-2 protein. Kidney Int (2002) 0.96

Pathophysiology of volume overload in acute heart failure syndromes. Am J Med (2006) 0.96

Hypertension and autosomal dominant polycystic kidney disease. Am J Kidney Dis (2011) 0.95

Increased vascular heme oxygenase-1 expression contributes to arterial vasodilation in experimental cirrhosis in rats. Hepatology (2004) 0.95

Erythropoietin ameliorates renal dysfunction during endotoxaemia. Nephrol Dial Transplant (2007) 0.94

CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiol Cell Physiol (2008) 0.94

Need to intervene in established acute renal failure. J Am Soc Nephrol (2004) 0.94

Systemic inhibition of the angiotensin-converting enzyme limits lipopolysaccharide-induced lung neutrophil recruitment through both bradykinin and angiotensin II-regulated pathways. J Immunol (2006) 0.93

Renal ultrasonographic evaluation in children at risk of autosomal dominant polycystic kidney disease. Am J Kidney Dis (2010) 0.93

Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail (2009) 0.93

Rapid microalbuminuria screening in type 2 diabetes mellitus: simplified approach with Micral test strips and specific gravity. Nephrol Dial Transplant (2004) 0.92

Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. Am J Kidney Dis (2005) 0.92

Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Kidney Int (2002) 0.92

The expression of aquaporin-1 in the medulla of the kidney is dependent on the transcription factor associated with hypertonicity, TonEBP. J Biol Chem (2010) 0.92

Identification and characterization of a novel hypertonicity-responsive element in the human aquaporin-1 gene. Biochem Biophys Res Commun (2002) 0.91

Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD). Kidney Int (2005) 0.91

Heart rate recovery predicts mortality and cardiovascular events in patients with type 2 diabetes. Med Sci Sports Exerc (2008) 0.91

Kidney failure: aims for the next 10 years and barriers to success. Lancet (2013) 0.91

Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. Am J Physiol Renal Physiol (2005) 0.91

Role of NF-kappaB and PI 3-kinase/Akt in TNF-alpha-induced cytotoxicity in microvascular endothelial cells. Am J Physiol Renal Physiol (2008) 0.90

Interaction between vasopressin and angiotensin II in vivo and in vitro: effect on aquaporins and urine concentration. Am J Physiol Renal Physiol (2010) 0.90

Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant (2012) 0.89

Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on blood pressure and the kidney. Am J Med (2003) 0.89

Differential effects of antihypertensive agents on electrocardiographic voltage: results from the Appropriate Blood Pressure Control in Diabetes (ABCD) trial. Am Heart J (2003) 0.89

Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. Am J Nephrol (2012) 0.88

Effect on stability, degradation, expression, and targeting of aquaporin-2 water channel by hyperosmolality in renal epithelial cells. Biochem Biophys Res Commun (2005) 0.88

Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2011) 0.87

Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD). Contemp Clin Trials (2005) 0.87

Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. Am J Physiol Renal Physiol (2005) 0.86

Downregulation of UT-A1/UT-A3 is associated with urinary concentrating defect in glucocorticoid-excess state. J Am Soc Nephrol (2008) 0.86

Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. J Card Fail (2004) 0.85

Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol (2004) 0.85

Outcome differences in community- versus hospital-acquired hyponatremia in patients with a diagnosis of heart failure. Circ Heart Fail (2013) 0.85

Effect of primary polydipsia on aquaporin and sodium transporter abundance. Am J Physiol Renal Physiol (2003) 0.85

Exercise capacity is a predictor of cardiovascular events in patients with type 2 diabetes mellitus. Diab Vasc Dis Res (2006) 0.85

Potential pharmacological interventions in polycystic kidney disease. Drugs (2007) 0.84

The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2011) 0.84

Diabetic autonomic neuropathy is associated with an increased incidence of strokes. Auton Neurosci (2003) 0.84

Effect of mineralocorticoid deficiency on ion and urea transporters and aquaporin water channels in the rat. Biochem Biophys Res Commun (2002) 0.84